A little-known ASX pharmaceutical stock is setting the bar high today.
Very high.
Shares in the medical device company closed yesterday trading for 2.7 cents. In morning trade on Wednesday, the ASX pharmaceutical stock leapt to 6.0 cents per share, up a whopping 122%.
After some likely profit-taking, at the time of writing shares are trading for 4.4 cents apiece, up a very healthy 63.0%.
For some context, the All Ordinaries Index (ASX: XAO) is down 0.3% at this same time.
Any guesses?
If you said Atomo Diagnostics Ltd (ASX: AT1), give yourself a virtual gold star.
Here's what's piquing investor interest in the microcap stock today.
What's sending the ASX pharmaceutical stock soaring?
The Atomo Diagnostics share price is rocketing higher after the company announced it had secured purchase orders from Viatris Healthcare for around $970,000 worth of HIV Self-Tests.
The test kits, manufactured by the ASX pharmaceutical stock under the Mylan brand, will be used to supply a number of low and middle income countries (LMICs).
The orders are for manufacture during the second half of FY 2024.
"We have seen growing demand during FY24 for the Atomo HIV Self-Test here in Australia as well as across branded versions supplied to international markets," Atomo CEO John Kelly said.
"Following significant increases in sales to Europe and in Australia, it is good to now see emergent demand across LMIC markets from our global health partner for HIV testing, Viatris," Kelly added.
The ASX pharmaceutical stock has commercialised a number of products across international markets. It has existing supply agreements for testing applications targeting infectious diseases including COVID-19, HIV, viral versus bacterial differentiation and female health.
